Alternatives
Alternatives to TrueMe
TrueMe scores 73/100 on our Cost-Efficiency Index . Here are other programs to consider, each scored the same way. Partners are listed first.
TrueMe at a glance
- Semaglutide
- $139/moMonth-to-month, same price at any dose, compounded; $89/mo on the 3-month plan, $267 charged at checkout
- Tirzepatide
- $149/moMonth-to-month, same price at any dose, compounded; $99/mo on the 3-month plan, $297 charged at checkout
- Coverage
- 6 states
- Brand-name GLP-1s
- No, compounded only
- Oral option
- No
- Pricing verified
- October 2026
2 of the 8 programs below list semaglutide for less than TrueMe's $139 a month. 0 of the 8 list tirzepatide for less than its $149 a month.
TrueMe is a cash-pay telehealth brand offering compounded semaglutide and tirzepatide with added B vitamins, alongside NAD+, sermorelin and glutathione.
Best for: Shoppers in its six states who want flat, all-inclusive GLP-1 pricing with no membership.
What TrueMe does well
- One price covers consultation, medication, shipping, supplies and provider support, and the site states there are no separate membership fees
- Same price at every dose, so the cost does not climb as a provider titrates the dose upward
- Full pricing is published up front — no intake form is required before you can see what you will pay
- Names its telehealth platform (Telegra) and physician network (Strive), and the returns address names CarePoint Infusion Pharmacy in Stafford, Texas
Why readers look for an alternative
- Serves only six states (AZ, CO, MO, PA, TX, WI), far narrower coverage than most national GLP-1 telehealth
- Prices marketed per month are charged every 4 weeks at checkout — 13 charges a year, not 12
- You pay before completing the medical intake, and approval is not guaranteed at the moment you are charged
- The 3-month rates ($89 and $99/mo) are a single upfront charge of $267 or $297, not a lower monthly plan
- No brand-name Wegovy or Zepbound; compounded semaglutide and tirzepatide only
- A Featured In strip shows CNN, Fox News, Forbes, New York Times and NPR logos with no linked coverage
- Partner01A94/ 100Index
CoreAge Rx
CoreAge Rx charges one flat price at every dose, $99 a month for semaglutide and $149 for tirzepatide, with no membership fee.
- Sema
- $99/mo
- Tirz
- $149/mo
- Coverage
- All 50 states
- Brand
- Compounded
Compared with TrueMe: $40/mo less for semaglutide
- 02C74/ 100Index
HealthSource
HealthSource offers compounded semaglutide and tirzepatide injections, plus oral tirzepatide, with physician care through MD Integrations and billing every four weeks.
- Sema
- $199 per 4 weeksStarting price, compounded
- Tirz
- $299 per 4 weeksStarting price, compounded
- Coverage
- All 50 states
- Brand
- Compounded
Compared with TrueMe: $60/mo more for semaglutide · $150/mo more for tirzepatide · offers an oral option
- 03C74/ 100Index
Fitstry
Fitstry, the GLP-1 program of the telehealth practice Weightstry, charges $249 every four weeks for compounded semaglutide, $339 for tirzepatide and $279 for a daily tablet, month to month, in 49 states.
- Sema
- $249Every 4 weeks (month-to-month, compounded; daily tablet $279)
- Tirz
- $339Every 4 weeks (month-to-month, compounded)
- Coverage
- 49 states
- Brand
- Compounded
Compared with TrueMe: $110/mo more for semaglutide · $190/mo more for tirzepatide · offers an oral option
- 04C74/ 100Index
Nucore Health
Nucore Health offers compounded semaglutide from $179 a month, tirzepatide from $269 and an oral semaglutide option from $209, with no membership fee.
- Sema
- $179/moAs low as; dose and plan terms need confirmation, compounded
- Tirz
- $269/moAs low as; dose and plan terms need confirmation, compounded
- Coverage
- All 50 states
- Brand
- Compounded
Compared with TrueMe: $40/mo more for semaglutide · $120/mo more for tirzepatide · offers an oral option
- 05C74/ 100Index
PrescrYbe
PrescrYbe lists compounded semaglutide at $249 and tirzepatide at $339 per four-week cycle before you start, with oral semaglutide at $279 and microdose plans at $179; a four-week cycle means 13 charges a year.
- Sema
- $249Every 4 weeks (compounded injection; oral $279, microdose $179)
- Tirz
- $339Every 4 weeks (compounded injection; microdose $179)
- Coverage
- All 50 states + DC
- Brand
- Compounded
Compared with TrueMe: $110/mo more for semaglutide · $190/mo more for tirzepatide · offers an oral option
- 06C74/ 100Index
Found Youth
Found Youth sells compounded semaglutide at $249 and tirzepatide at $329 for a one-month term, with cheaper three- and six-month terms paid up front, and names the Miami pharmacy that fills every order.
- Sema
- $249/mo1-month term, compounded; $669 for 3 months or $1,259 for 6 months, each paid up front
- Tirz
- $329/mo1-month term, compounded; $849 for 3 months or $1,599 for 6 months, each paid up front
- Coverage
- Multi-state
- Brand
- Compounded
Compared with TrueMe: $110/mo more for semaglutide · $180/mo more for tirzepatide · offers an oral option
- 07C73/ 100Index
Luma Health Co
Luma Health Co publishes a four-week dose-by-dose price list for compounded semaglutide and tirzepatide, with care from a named nurse practitioner.
- Sema
- $115For a 4-week supply (0.25 mg starting dose, compounded; higher doses cost more)
- Tirz
- $180For a 4-week supply (2.5 mg starting dose, compounded; higher doses cost more)
- Coverage
- 30 states
- Brand
- Compounded
Compared with TrueMe: $24/mo less for semaglutide · $31/mo more for tirzepatide
- 08C73/ 100Index
MyFastRx
MyFastRx is a cash-pay compounded-GLP-1 platform with a full published price ladder: a $139/mo semaglutide and $199/mo tirzepatide standing month-to-month rate, a discounted first month with a promo code.
- Sema
- $139/moAll doses, promotional rate, compounded
- Tirz
- $199/moAll doses, promotional rate, compounded
- Coverage
- All 50 states
- Brand
- Compounded
Compared with TrueMe: $50/mo more for tirzepatide
Assume any provider we list may compensate us — it never changes the Cost-Efficiency Index. Pricing and coverage reflect public disclosures at last review; confirm on each provider's site. Not medical advice. See our disclosure.